VA Healthcare & Services Contracts — August 29, 2026

OptumRx secured two $106.3M delivery orders via full-and-open competition, confirming its PBM platform is preferred by the VA over rivals like CVS Health (CVS) and Cigna (CI).

Both contracts are firm-fixed-price, meaning OptumRx bears all cost overruns if claims volume or drug prices spike unexpectedly during the three-month performance windows.

Despite $212.6M in total obligations, $0 has been outlayed, indicating no funds disbursed yet—raising questions about contract execution pace or VA payment processing bottlenecks.

OptumRx must deliver PBM services for two consecutive three-month periods (Oct-Dec 2025 and Jan-Mar 2026) under firm-fixed-price contracts with no cost buffers; any claims volume surge or drug price volatility could compress margins on $212.6M in revenue.

Both contracts are from the same agency (VA) for the same service (PBM) with the same recipient (OptumRx), creating a $212.6M single-agency concentration risk for UNH's government PBM revenue.

The contracts cover only Q1 and Q2 FY25; no follow-on awards for Q3 or Q4 have been announced, leaving a potential $212.6M revenue gap for OptumRx in the second half of FY25 if VA does not renew.

OptumRx's dual $106.3M wins imply a $425M annualized VA PBM spending run rate, suggesting potential for expanded PBM contracts across other civilian agencies (e.g., HHS, DHA) if OptumRx executes well.

OptumRx's competitive wins against CVS Caremark and Express Scripts signal potential market share gains in the $100B+ federal PBM market, including DoD's TRICARE program.

The VA's award of two $106.3M PBM contracts to OptumRx on the same day suggests a trend toward consolidating pharmacy benefit management under large, integrated PBMs like OptumRx, rather than multiple smaller vendors.

Both VA contracts are firm-fixed-price, shifting cost risk to the contractor—a departure from cost-plus models common in healthcare services, which could compress margins for PBMs in government contracts.

{"entity" => "UnitedHealth Group (UNH)", "reason" => "OptumRx won $212.6M in VA PBM contracts with zero outlays and short performance windows, creating lumpy revenue and margin risk.", "trigger" => "VA announcement of FY25 Q3-Q4 PBM awards; UNH Q1 2026 earnings for government segment margins"}

{"entity" => "CVS Health (CVS)", "reason" => "CVS Caremark lost two consecutive VA PBM contracts to OptumRx, signaling potential market share erosion in federal PBM.", "trigger" => "CVS Q4 2025 earnings commentary on federal PBM pipeline; VA PBM re-compete announcements"}

{"entity" => "Cigna Group (CI)", "reason" => "Express Scripts also lost to OptumRx in full-and-open competition, indicating competitive weakness in government PBM.", "trigger" => "Cigna Q4 2025 earnings; VA PBM solicitation results for FY26"}

{"entity" => "Department of Veterans Affairs", "reason" => "VA awarded $212.6M in PBM contracts but has not outlayed any funds, suggesting potential payment delays or budget constraints.", "trigger" => "VA FY26 budget request; GAO report on VA payment timeliness"}